Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06342947 · ClinicalTrials.gov registry record · Phase 2
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
A Phase 2 study of Nonalcoholic Steatohepatitis and NASH, sponsored by Aligos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 20
- Study locations
NCT06342947 is a Phase 2 study of Nonalcoholic Steatohepatitis and NASH that has completed, run by Aligos Therapeutics. The registered enrollment target is 102 participants, below the 1,024-participant average among 17 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06342947, a Phase 2 study of Nonalcoholic Steatohepatitis and NASH, has completed, sponsored by Aligos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin \[softgel\] capsule) for 12 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALG-055009
Study Locations (20)
Florida
- Aligos Clinical Study Site 26 - Bradenton
- Aligos Clinical Study Site 25 - Clearwater
- Aligos Clinical Study Site 39 - Fort Myers
- Aligos Clinical Study Site 2 - Maitland
- Aligos Clinical Study Site 22 - Ocoee
- Aligos Clinical Study Site 32 - Port Orange
- Aligos Clinical Study Site 38 - Sarasota
- Aligos Clinical Study Site 31 - The Villages
- Aligos Clinical Study Site 3 - Viera
- Aligos Clinical Study Site 30 - Winter Park
California
- Aligos Clinical Study Site 35 - Chula Vista
- Aligos Clinical Study Site 1 - Lincoln
- Aligos Clinical Study Site 37 - Poway
- Aligos Clinical Study Site 10 - Rialto
Arizona
- Aligos Clinical Study Site 18 - Chandler
- Aligos Clinical Study Site 15 - Peoria
- Aligos Clinical Study Site 17 - Tucson
Georgia
- Aligos Clinical Study Site 23 - Athens
Kansas
- Aligos Clinical Study Site 12 - Topeka
Kentucky
- Aligos Clinical Study Site 29 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2024-09-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06342947
The ClinicalTrials.gov registry entry for NCT06342947 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,024-participant average among 17 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (90% lower). The listed sponsor is Aligos Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06342947 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06342947 about?
NCT06342947 is a clinical study titled "ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)". This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin \[softgel\] capsule) for 12 weeks.
What is the current status of trial NCT06342947?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2024-04-01. Estimated completion is 2024-09-09.
What conditions does trial NCT06342947 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis, NASH, Metabolic Dysfunction-associated Steatohepatitis, MASH.
What interventions are being tested in trial NCT06342947?
The interventions under investigation include: Placebo (DRUG), ALG-055009 (DRUG).
Who is sponsoring clinical trial NCT06342947?
This trial is sponsored by Aligos Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06342947 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
ACTIVE NOT RECRUITING · Phase 2
-
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.